Stephanie Evans, MD
Family Medicine · Albuquerque, NMNPI 1144251778
Payments from drug & device makers
Across 93 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$272
- Boehringer Ingelheim$224
- Astellas Pharma US Inc$221
- AstraZeneca$192
- Novo Nordisk$174
- Lilly USA, LLC$134
- plus $599 from 13 others
What the payments were for
- Food & beverage$1,817100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 11 | $272 |
| Boehringer Ingelheim | 8 | $224 |
| Astellas Pharma US Inc | 10 | $221 |
| AstraZeneca | 13 | $192 |
| Novo Nordisk | 8 | $174 |
| Lilly USA, LLC | 8 | $134 |
| GSK | 6 | $116 |
| Novartis | 4 | $74 |
| Merck | 6 | $74 |
| Exact Sciences | 4 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Johnson & Johnson | 2 | $40 |
| AbbVie | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Pfizer | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Abbott | 1 | $18 |
How this compares
$1,817 in reported general payments places this provider in the 85th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 75 | $82,094 |
| EliquisApixaban | 79 | $78,754 |
| OzempicSemaglutide | 79 | $78,251 |
| TrulicityDulaglutide | 40 | $68,591 |
| MyrbetriqMirabegron | 65 | $45,758 |
| FarxigaDapagliflozin Propanediol | 37 | $27,704 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $26,444 |
| Spiriva RespimatTiotropium Bromide | 23 | $18,402 |
| MounjaroTirzepatide | 17 | $17,304 |
| Levothyroxine Sodium | 774 | $11,488 |
| Atorvastatin Calcium | 716 | $9,878 |
| Losartan Potassium | 504 | $9,467 |
| Arnuity ElliptaFluticasone Furoate | 28 | $8,675 |
| LinzessLinaclotide | 11 | $8,538 |
| Gabapentin | 516 | $7,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $134 | $85,89657 claims |
| Johnson & JohnsonXarelto | $40 | $82,09475 claims |
| PfizerEliquis | $26 | $78,75479 claims |
| Novo NordiskOzempic | $174 | $78,25179 claims |
| AstraZenecaFarxiga, Symbicort | $192 | $54,148106 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $45,75865 claims |
| Boehringer IngelheimSpiriva Respimat | $224 | $18,40223 claims |
| GSKArnuity Ellipta | $116 | $8,67528 claims |
| AbbVieLinzess | $38 | $8,53811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Albuquerque
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
- Sally FisherAlbuquerque$1.8M
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Michael MontoyaAlbuquerque$7K
- Yvonne Vanarsdale-ImaniAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.